The German pharmaceutical company responsible for the anticoagulant drug, Pradaxa, offered a $650 million settlement package to wrap up thousands of Pradaxa lawsuits in the U.S. In the statement announcing the proposed settlement, the company, Boehringer Ingelheim, did not accept blame for Pradaxa injuries, the most prevalent among them being excessive bleeding events.
In deflecting responsibility, Boehringer Ingelheim also called the Pradaxa lawsuits a distraction.
Furthermore, the head of the company’s legal department expressed disfavor for trials decided by jury. According to the company’s statement, if all of the Pradaxa lawsuits in the U.S. were to go to trial, they would be decided by juries who most likely would have little to no experience with pharmaceutical and scientific matters, thus, creating a situation where Boehringer Ingelheim would be unable to determine a general verdict.
It appears then that the German pharmaceutical company’s decision to settle was based purely on distraction and uncertainty, rather than accepting responsibility for the serious injuries some patients have sustained while using Pradaxa.
As a national law firm practicing defective drug litigation, Carey Danis & Lowe is dedicated to providing legal assistance to individuals and families who have been affected by faulty pharmaceutical products, such as Pradaxa. If you or someone you love has been injured by Pradaxa, we encourage you to contact one of our experienced defective drug lawyers to begin exploring legal options. We believe that when pharmaceutical companies release a potentially dangerous product onto the market, they must take responsibility for the harm inflicted by such a product.
Carey Danis & Lowe offers free initial case evaluations. Discuss your case with one of our lawyers today, and find out if you are eligible for compensation.
Share your Pradaxa story with Carey Danis & Lowe. Contact us by phone at 800.721.2519.References: Pharmaceutical litigation, Pradaxa